NCT06924359
Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease
Recruiting · Not specified · Peking University First Hospital · registry updated 2026-09-29
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).
Inclusion
- Male or female participants aged ≥ 50 years;
- Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN);
- Signed informed consent form
Exclusion
- Presence of other neurological disorders and systemic diseases that may cause cognitive impairment;
- Inability to cooperate with cognitive assessments;
- Refusal to undergo blood sampling.